Treatment of posterior uveitis with a fluocinolone acetonide implant - Three-year clinical trial results
Treatment of posterior uveitis with a fluocinolone acetonide implant - Three-year clinical trial results
复制标题
DOI：
10.1001/archopht.126.9.1191
复制
发表时间：
2008-09-01
影响因子：
--
通讯作者：
Comstock, Timothy L.
中科院分区：
文献类型：
--
作者：
Callanan, David G.;Jaffe, Glenn J.;Comstock, Timothy L.
目的：评价0.59 mg和2.1 mg醋酸氟轻松（FA）玻璃体内植入物治疗非感染性后葡萄膜炎的安全性和有效性。设计：一项为期3年的多中心、随机、历史对照试验，在110例患者中植入0.59 mg FA玻璃体内植入物，在168例患者中植入2.1 mg FA玻璃体内植入物。主要结果指标：结果：对于0.59 mg剂量组，植入眼的葡萄膜炎复发率从62%（植入前1年期间）分别降至植入后1年、2年和3年期间的4%、10%和20%（P
Objectives: To evaluate the safety and efficacy of 0.59- mg and 2.1-mg fluocinolone acetonide ( FA) intravitreous implants in noninfectious posterior uveitis.Design: A 3-year, multicenter, randomized, historically controlled trial of the 0.59- mg FA intravitreous implant in 110 patients and the 2.1-mg FA intravitreous implant in 168 patients.Main Outcome Measures: Recurrence rate, vision, and complications.Results: Uveitis recurrence was reduced in implanted eyes from 62% (during the 1-year preimplantation period) to 4%, 10%, and 20% during the 1-, 2-, and 3- year postimplantation periods, respectively, for the 0.59-mg dose group (P